MOTS-c

MOTS-c is one of the more genuinely unusual entries on this site, and the reason has to do with where its gene lives. Almost every peptide covered here is either an endogenous hormone encoded in the nuclear genome or a synthetic fragment of one. MOTS-c is neither. It is a 16-amino-acid peptide encoded within a short open reading frame inside the mitochondrial 12S ribosomal RNA gene — meaning the sequence for MOTS-c is written not on chromosomes in the cell nucleus but on the small circular DNA molecule inside the mitochondrion. It belongs to a young class of molecules called mitochondrial-derived peptides (MDPs) that is redrawing what we thought we knew about the coding capacity of the mitochondrial genome.

The compound was first characterised in 2015 by Changhan Lee, Pinchas Cohen and colleagues at USC in a Cell Metabolism paper that has become the foundational reference. Their central proposal was that MOTS-c functions as a retrograde signal — meaning the mitochondrion is sending a message outward, to the rest of the cell and to distant tissues, about its own metabolic state. That framing matters because for most of the history of cell biology the flow of information was assumed to run in the other direction: the nucleus tells the mitochondrion what to do. MDPs suggest the conversation is a two-way exchange, and MOTS-c is one of the messengers.

Where the story leaves the frontier biology and enters the peptide-therapy landscape is with the downstream effects that Lee 2015 and follow-up work describe: activation of AMP-activated protein kinase (AMPK) in skeletal muscle, improvements in glucose uptake and insulin sensitivity, and — most eye-catching — reported exercise-mimetic effects on running capacity in aged mice (Reynolds 2021 Nature Communications). These are real findings in real preclinical models, and the mechanism ties into pathways that are well understood in metabolic biology. It is a coherent scientific story.

The human evidence is where honesty is required. There is no completed phase-2 or phase-3 randomised interventional trial of exogenous MOTS-c as a therapeutic. What does exist is a growing body of correlational studies measuring circulating MOTS-c levels across human populations: lower levels have been reported in aged, obese, and type 2 diabetic populations compared with younger and metabolically healthy controls. Those observations are consistent with the preclinical mechanism story, but they are correlational — they do not demonstrate that giving exogenous MOTS-c to humans produces the corresponding metabolic improvements. That is the critical gap that a page representing the primary literature has to name.

MOTS-c is one of the more genuinely unusual entries on this site, and the reason has to do with where its gene lives. Almost every peptide covered here is either an endogenous hormone encoded in the nuclear genome or a synthetic fragment of one. MOTS-c is neither. It is a 16-amino-acid peptide encoded within a short open reading frame inside the mitochondrial 12S ribosomal RNA gene — meaning the sequence for MOTS-c is written not on chromosomes in the cell nucleus but on the small circular DNA molecule inside the mitochondrion. It belongs to a young class of molecules called mitochondrial-derived peptides (MDPs) that is redrawing what we thought we knew about the coding capacity of the mitochondrial genome.

The compound was first characterised in 2015 by Changhan Lee, Pinchas Cohen and colleagues at USC in a Cell Metabolism paper that has become the foundational reference. Their central proposal was that MOTS-c functions as a retrograde signal — meaning the mitochondrion is sending a message outward, to the rest of the cell and to distant tissues, about its own metabolic state. That framing matters because for most of the history of cell biology the flow of information was assumed to run in the other direction: the nucleus tells the mitochondrion what to do. MDPs suggest the conversation is a two-way exchange, and MOTS-c is one of the messengers.

Where the story leaves the frontier biology and enters the peptide-therapy landscape is with the downstream effects that Lee 2015 and follow-up work describe: activation of AMP-activated protein kinase (AMPK) in skeletal muscle, improvements in glucose uptake and insulin sensitivity, and — most eye-catching — reported exercise-mimetic effects on running capacity in aged mice (Reynolds 2021 Nature Communications). These are real findings in real preclinical models, and the mechanism ties into pathways that are well understood in metabolic biology. It is a coherent scientific story.

The human evidence is where honesty is required. There is no completed phase-2 or phase-3 randomised interventional trial of exogenous MOTS-c as a therapeutic. What does exist is a growing body of correlational studies measuring circulating MOTS-c levels across human populations: lower levels have been reported in aged, obese, and type 2 diabetic populations compared with younger and metabolically healthy controls. Those observations are consistent with the preclinical mechanism story, but they are correlational — they do not demonstrate that giving exogenous MOTS-c to humans produces the corresponding metabolic improvements. That is the critical gap that a page representing the primary literature has to name.

The MOTS-c research base has a distinctive structure: a small number of very high-impact foundational papers, a growing preclinical follow-up literature, and a rapidly expanding but almost entirely correlational human circulating-level dataset. Reading it honestly requires distinguishing the three layers.

The foundational paper is Lee et al. Cell Metabolism 2015. This is where MOTS-c was named and its unusual biology characterised: the discovery that a short open reading frame within the mitochondrial 12S ribosomal RNA encodes a 16-amino-acid peptide that is exported from mitochondria, activates AMPK in skeletal muscle, and produces measurable improvements in glucose handling and insulin sensitivity in mouse models. This paper reframed the mitochondrial genome as a source of signalling peptides. It is a paradigm paper for the mitochondrial-derived-peptide research area.

The exercise-mimetic finding — Reynolds et al. Nature Communications 2021 — is the most cited follow-up work. In aged mice, exogenous MOTS-c improved running capacity, skeletal muscle metabolism, and multiple aging-related endpoints. The result received substantial popular coverage as evidence that MOTS-c behaves as an 'exercise-in-a-vial' mimic. Read carefully, the paper is more measured than its coverage: it demonstrates preclinical effects in a mouse model of aging, and it opens the question of whether analogous effects could be demonstrated in human trials. That question is not yet answered.

The human evidence base is almost entirely circulating-level correlational: cross-sectional studies measuring endogenous MOTS-c in different human populations and finding lower levels associated with older age, obesity, and type 2 diabetes (representative work: Yin 2022 and multiple contemporaneous studies). Correlational associations of this kind are consistent with the preclinical mechanism story, and they are not trivial to obtain. But they do not demonstrate that giving exogenous MOTS-c to humans produces the corresponding metabolic improvements — that is a completely different study design, and it has not been performed at scale.

Kim et al. FASEB Journal 2018 extended the preclinical work into cardiovascular and metabolic disease models, adding evidence that MOTS-c administration produces reproducible effects in additional mouse contexts. Merry et al. 2020 is a useful consolidating review of the mitochondrial-derived-peptide field, situating MOTS-c within the broader MDP class (which also includes humanin and the SHLPs).

MOTS-c has never had an FDA-authorised commercial product, has never completed a phase-2 randomised placebo-controlled human trial, and does not have an active phase-3 development program under any sponsor known to public regulatory registries. That is the essential regulatory position, and it reflects the compound's status as a research-frontier molecule rather than a therapeutic near approval.

The compound's biological interest is genuine and increasing: mitochondrial-derived peptides are a growing research area with several publications per year, and MOTS-c is the most-studied member of the class. That academic-research trajectory is not the same as a pharmaceutical development pathway, and consumers should not read scientific momentum in the literature as regulatory progress toward approval.

The WADA prohibited list does not currently include MOTS-c by name, but competitive athletes should be aware that peptides proposed to enhance exercise capacity or metabolic performance may attract prohibited-substance scrutiny under the S0 or S2 categories depending on framing. Verify current WADA status before use in any competitive context.